Eisai, a leading global research and development-based pharmaceutical company, today opened a new facility at its EMEA Knowledge Centre in Hatfield UK to handle the packaging of its investigational compound lenvatinib, for the treatment of advanced thyroid cancer. This represents a foreign direct investment of more than £8 million into the UK by the Japanese company.
"We are extremely proud of this new development at our EMEA Knowledge Centre. The UK is an ideal location for advanced manufacturing. We are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy,” Mr Haruo Naito, CEO of Eisai Co., Ltd. said....show more
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.